<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03563989</url>
  </required_header>
  <id_info>
    <org_study_id>K171009J</org_study_id>
    <nct_id>NCT03563989</nct_id>
  </id_info>
  <brief_title>STENTYS Xposition S in the Treatment of Chronic Total Artery Occlusion</brief_title>
  <acronym>SXS-CTO</acronym>
  <official_title>STENTYS Xposition S in the Treatment of Chronic Total Artery Occlusion (SXS-CTO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intro: Chronic total occlusions (CTO) are the most severe coronary lesions. Negative distal
      vessel remodeling occurs in these lesions, leading to reduction of artery diameter. Treatment
      of CTO with percutaneous coronary intervention (PCI) is associated with good clinical
      outcomes. However, QCA and IVUS studies showed a notable lumen and vessel enlargement distal
      to recanalized CTO. In addition, optical tomography (OCT) studies showed high rates of stent
      strut malapposition and incomplete stent strut coverage after CTO PCI. The Stentys Xposition
      S is a self-apposing stent device which lowers stent strut malapposition rates. Its safety
      and effectiveness has been demonstrated in STEMI and stable coronary patients but never
      investigated in CTO lesions.

      Hypothesis/Objective To investigate whether self-expanding stents are more effective than
      balloon-expandable stents for reducing stent malapposition at 6 months after implantation in
      patients with CTO undergoing percutaneous coronary intervention.

      Method Pilot randomized study. Patients are randomized to receive either self-expandable
      stent or balloon expandable stent to perform CTO-PCI. Follow-up coronary angiography is
      performed at 6 months post-PCI. Stent malapposition is evaluated by OCT.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 26, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>strut malapposition at six months measured by OCT</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of uncovered struts</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lumen diameter (mm)</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Restenosis</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Angina pectoris</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dyspnea</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>6 months after CTO-PCI</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Chronic Total Occlusion</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Stentys Xposition S Self-Apposing stent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>STENTYS Xposition S Sirolimus Eluting Self-Apposing Coronary Stent System</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Balloon-expandable stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional Balloon-expandable drug eluting stents in effect at the time of the study, in compliance with applicable contracts made between Hospital and suppliers.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantation of Stent (PCI)</intervention_name>
    <description>Treatment of CTO with Percutaneous Coronary Intervention (PCI) Patients are randomized to receive either self-expandable stent or balloon expandable stent</description>
    <arm_group_label>Conventional Balloon-expandable stent</arm_group_label>
    <arm_group_label>Stentys Xposition S Self-Apposing stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age ≥ 18 years;

          -  CTO referred for PCI

          -  Diameter of the Target vessel for PCI between 2.5 and 4.5mm

          -  Agreement to participate and signed informed consent after information

          -  Affiliation to Social Security System

          -  French comprehension

        Exclusion Criteria:

          -  Pregnant women, breast-feeding,

          -  History of an allergic reaction or significant sensitivity to any stent component or
             to contrast dye

          -  Intrastent CTO

          -  Major calcifications in the CTO

          -  Inclusion in another interventional study

          -  Person under guardianship or curatorship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assistance Publique Hôpitaux de Paris - CHU HENRI MONDOR</name>
      <address>
        <city>Créteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MADJID BOUKANTAR, MD</last_name>
      <phone>+33149812111</phone>
      <email>madjid.boukantar@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <study_first_submitted>May 28, 2018</study_first_submitted>
  <study_first_submitted_qc>June 10, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2018</study_first_posted>
  <last_update_submitted>August 10, 2018</last_update_submitted>
  <last_update_submitted_qc>August 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic total occlusion</keyword>
  <keyword>Self-expandable stent</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Coronary artery disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>DATAS ARE OWN BY ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS, PLEASE CONTACT SPONSOR FOR FURTHER INFORMATION</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

